CYBN (Cybin Corp) Net earnings per share growth this year

Official company branding of Cybin (CYBN)

Cybin Inc. minimizes capital expenditures by outsourcing drug synthesis to external contractors. The distribution of the annual change in earnings per share confirms the financial trajectory, where 24.60 shows the current value of the metric. Potential revenue is expected from insurance reimbursements for depression therapy. The company is currently maximizing its research resources as it prepares to release innovative psilocybin-based molecules.

CYBN (cybin.com) Earnings per share growth in current year history from 07/04/2022 to 01/05/2026

Comprehensive metric breakdowns and analytics for cybin.com (CYBN)

- stock value and consensus price forecast:
Market Price Cybin|CYBN - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Cybin Inc.|CYBN - Enterprise Value
- company book value details:
Accounting Value of a Share Cybin|CYBN - Company Book Value|Market-to-Book Ratio cybin.com|CYBN - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Cybin Inc.|CYBN - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Cybin|CYBN - Company Aggregate Debts|Debt to Book Capitalization Ratio Cybin Inc.|CYBN - Company Long-Term Debts|Short-Term Debt Volume Cybin|Immediate Liquidity Ratio cybin.com
- net income and valuation multiples indicators:
CYBN - Net Income|Expected Net Income Cybin Inc.|CYBN - P/E Multiple|Market Cap to Projected Earnings Cybin|CYBN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Cybin Inc.|CYBN - Operating profit EBITDA|Net earnings per share for the last 12 months Cybin|CYBN - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months cybin.com|CYBN - Earnings growth in current year|Expected earnings per share growth for next year Cybin Inc.
Fundamental valuation:Cybin Corp, CYBN
Core merchandise of Cybin Inc.

The long-term reliability of an issuer is determined by its ability to generate growing profits, which is reflected in the EPS YoY dynamics by calculating the percentage deviation of current earnings per share from the previous year's figures. For Cybin Inc. (CYBN), which is developing innovative psychedelic therapies for depression, this indicator serves as a marker for the transition from the R&D investment stage to the drug commercialization phase.

Direct competitors

Earnings per share growth rate in current year Alkermes PLC (ALKS)|AVDL (Avadel Pharma) - Earnings growth in current year|Net earnings per share growth this year atai (ATAI)|Earnings growth in current year GHRS|MNMD (mindmed.co) - Earnings per share increase in current year|Earnings per share growth in current year COMPASS Pathways CMPS|LB Pharmaceuticals, Inc. (LBRX) - Earnings per share growth rate in current year|Bright Minds Biosciences Inc - Earnings growth in current year|Vanda (VNDA) - Net earnings per share growth this year|ANRO (Alto Neuroscience, Inc.) - Net earnings per share growth this year|Earnings per share growth rate in current year nrxpharma.com (NRXP)|CING (Cingulate Inc) - Earnings growth in current year|Earnings per share growth in current year SILO|Earnings growth in current year CPHI|Expected net earnings per share growth this year clearmindmedicine.com|Earnings per share growth in current year Psyence Biomedical Ltd. PBM|SPRC: Earnings per share growth this year|SEEL: Net earnings per share growth this year|Earnings per share increase in current year VRPX (Virpax Pharmaceuticals)|KRTX: Earnings growth in current year